Global Pharmaceutical and Biotechnology Outlook 2014 - Japan Pharma

Published: January 2014
No. of Pages: 141
Price: Single User: US $ 2500  US $ 2250 Corporate User: US $ 7500  US $ 6750
    ReportsandReports

This report is available at 10% Discount till 31 December 2017. To avail discount please contact at +1-888-391-5441 / sales@reportsandreports.com.


2014 will be marked as a transition year for the Japanese Pharma industry - the year is bound to be painful both for innovators and generic companies due to the new regulations.  We find these regulations to be 'decisive' in spurring generic penetration significantly, with the main beneficiary being the Japanese government (or society) and not the generic companies.  The implications of new price-reversions are going to have many facets and will change conventional business models.  We expect many support services industries - CMOs, CROs and other allied services industries to benefit from these structural changes, while API importers will suffer.  We also expect consolidation and M&A activities to spur in Japan.

Innovation Takes the Driver's Seat:  While the new regulations will change the current business philosophy of doing business in patent expired space (>45% to total Japan market), the policy makers also discourage 'me too' innovations at the same time. The regulators however tend to support the 'first time in the world' level innovations by providing 'innovation premiums'.  Japanese innovators will now become more serious and selective in their R&D approach.  Previous year the Japanese innovators have focused on acquiring assets in - autoimmune, orphan diseases and oncology fields (Annexure 5).  We expect this trend to prevail in the coming years.  We find some of the candidates to remain in the limelight in 2014 along with some new additions - Edoxaban (Daiichi Sankyo), Invokana (Mitsubishi Tanabe), Dolutegravir (Shionogi), BBI-608 (Dainippon Sumitomo), Vedolizumab (Takeda), Xtandi (Astellas), Nivolumab (Ono) to hand-pick a few of them. The reports explain detail analysis on these key candidates.

The 138 pages report contains the detailed discussion of Japan biopharmaceutical market – which includes- Our view on the impact of 2014 price cuts on generic companies and innovator companies and detailed discussion on key attributes (consolidation activities, potential of R & D pipeline candidates, generic threat in domestic Japan market etc…) of leading Japanese innovator companies- Astellas, Chugai, Daiichi Sankyo, Dainippon Sumitomo,  Eisai, Kyorin, Kyowa hakko Kirin, Mitsubishi Tanabe, Shionogi,  Takeda and  leading Japanese generic companies- Nippon Chemiphar, Sawai and Towa.

Published By: MP Advisors
Product Code: Access China Management Consulting Ltd14


Did you find what you are/were looking for ? If not, read below and browse through other relevant pages for similar market research reports OR get in touch with us through the form/contact info in your right navigation panel and well share relevant market report titles for you to explore.

Related Reports:

  • Global Reconstruction Meshes Market Research Report 2017-2022 by Players, Regions, Product Types & Applications

    The global Reconstruction Meshes market is valued at XX million USD in 2016 and is expected to reach XX million USD by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. This report offers an overview of the market trends, drivers, a...

  • Global Reconstruction Meshes Detailed Analysis Report 2017-2022

    This report mainly introduces volume and value market share by players, by regions, by product type, by consumers and also their price change details. As a Detailed Analysis report, it covers all details inside analysis and opinion in Reconstruction ...

  • Rheumatoid Arthritis - Pipeline Review, H2 2017

    Rheumatoid Arthritis - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Rheumatoid Arthritis - Pipeline Review, H2 2017, provides an overview of the Rheumatoid Arthritis (Immun...

  • Canavan Disease - Pipeline Review, H2 2017

    Canavan Disease - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Canavan Disease - Pipeline Review, H2 2017, provides an overview of the Canavan Disease (Central Nervous Syst...

  • Metachromatic Leukodystrophy (MLD) - Pipeline Review, H2 2017

    Metachromatic Leukodystrophy (MLD) - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Metachromatic Leukodystrophy (MLD) - Pipeline Review, H2 2017, provides an overview of the...

  • Encephalopathy - Pipeline Review, H2 2017

    Encephalopathy - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Encephalopathy - Pipeline Review, H2 2017, provides an overview of the Encephalopathy (Central Nervous System)...

  • Myocardial Fibrosis - Pipeline Review, H2 2017

    Myocardial Fibrosis - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Myocardial Fibrosis - Pipeline Review, H2 2017, provides an overview of the Myocardial Fibrosis (Cardiova...

  • Vaginal Atrophy (Atrophic Vaginitis) - Pipeline Review, H2 2017

    Vaginal Atrophy (Atrophic Vaginitis) - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Vaginal Atrophy (Atrophic Vaginitis) - Pipeline Review, H2 2017, provides an overview of...

  • Non-Small Cell Lung Cancer - Pipeline Review, H2 2017

    Non-Small Cell Lung Cancer - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Non-Small Cell Lung Cancer - Pipeline Review, H2 2017, provides an overview of the Non-Small Cell ...

  • Colon Cancer - Pipeline Review, H2 2017

    Colon Cancer - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Colon Cancer - Pipeline Review, H2 2017, provides an overview of the Colon Cancer (Oncology) pipeline landscape....


Why ReportsnReports.com?

  • 500,000 market research reports and growing.
  • Top Fortune 500 Organizations trust us for research data.
  • 24/7 support on call as well as emails.
  • Your Details are safe with us.
  • Free support for your research requirements.
  • Report Delivery: Email
  • Delivery Time:
    • Upto 24 hrs - working days
    • Upto 48 hrs max - weekends and public holidays

Research Support / Custom Research

If this business study does not have the data and information analysis you need, contact us with your research requirements. We explore available market research reports to map your needs and share report titles with you. Alternatively, we can also offer custom research that suits your budget and timelines. Share your information requirements here.
Connect With Us
Email: sales@reportsandreports.com Call : + 1 888 391 5441

Subscription Option

Using our subscription option, you get access to market research reports and industry data of Consumer Goods market as per your needs. Get the best of Consumer Goods research reports by utilizing your research budgets in an optimum way.

More about our Subscription option
Report Alerts

Get Email alerts about market research reports from industries and publishers of your interest: